Navigation Links
Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
Date:3/6/2008

BOTHELL, Wash., March 6 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it aligned the power of its leading product brands (Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R)), squarely behind the Cardiac Science(TM) brand.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO)

"We believe our solitary focus on noninvasive cardiology elevates our product and service offerings and differentiates us in the medical devices field," said John Hinson, Cardiac Science president and chief executive officer. "Going forward, our 95-year heritage and track record, comprehensive product and service offerings, and the strengths of our predecessor companies will be concentrated into a single, overarching story of dependability."

"Our products, employees, and culture are rooted in dependability," began Allan Criss, senior vice president of sales, marketing, and service. "The new Cardiac Science identity communicates our promise more clearly: We intend to be the company the global community thinks of first for high-quality noninvasive products and services. Our customers can -- and do -- depend on us, no matter what."

The new "shielded heart" logo represents the protective nature of the business. Cardiac Science products diagnose heart disease, resuscitate victims of sudden cardiac arrest, and help people get on with their lives with top-of-the-line cardiac rehabilitative equipment. The orange color represents the warmth, energy, and approachability of the brand.

"The company is dependable. Their products -- their treadmills, stress systems, ECG devices, connectivity, computer telemetry, printing mechanisms, and more -- the whole apparatus works well together," said Dr. Diana Westerfield, D.O., chief of staff, Barnes-Jewish St. Peter's Hospital in St. Peter's, MO, and member of the Missouri Advisory Committee for the Prevention of Heart Disease and Stroke. "I just don't see the Cardiac Science stuff break down. And if there is an issue, the Cardiac Science folks show up quickly -- more so than other companies we deal with."

The company issued a corporate brochure (http://www.cardiacscience.com/pdf/080201CSCBrochure.pdf), now available for download on its website, to clearly explain the benefits of its products and services.

Tony Titus, Cardiac Science vice president of marketing, said, "We believe the new brand initiative will strengthen our marketing and save the company money by consolidating our efforts. We expect to raise overall awareness of the Cardiac Science brand, our unique offerings, and expect to increase sales and goodwill among our customers."

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward Looking Statements

This press release contains forward-looking statements. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include the risk that the Company's new branding initiative may not result in more effective marketing, or increase sales, of the Company's products and services and may not save the Company money, as well as other risks that are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2006. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Company Contact: Investor Contact: Media Contact:

Mike Matysik Jenifer Kirtland Christopher Gale

Cardiac Science Corporation EVC Group, Inc. EVC Group, Inc.

Sr. Vice President and CFO (415) 896-6820 (201) 646-5431

(425) 402-2009 (203) 570-4681

cgale@evcgroup.com


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business
2. New research shows that iPods do not interfere with cardiac pacemakers
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
5. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
6. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
7. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
8. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
9. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
10. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
11. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):